EXP THER MED 润色咨询

Experimental and Therapeutic Medicine

出版年份:2010 年文章数:8422 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:4.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2023-01-17 氢弹 来自四川省

    大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。

    5

    展开5条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2022-06-29 骞骞F文章

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的

    5

    展开5条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2022-11-14 ms3000000235546431

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2020-09-23 ms8000000548825590

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:颗粒物;毒理
    经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?

    8

    展开8条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2022-10-18 ms5000001622730751

    偏重的研究方向:药理;中药复方
    经验分享:请问收网络药理加实验吗

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2020-09-07 ms5000000364586422

    审稿速度:12.0 | 投稿命中率:50.0
    经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2022-05-11 ms6000001101669014

    去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。
    请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?

    4

    展开4条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2022-08-29 ms5000001731462752

    审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2022-08-11 乐心肠

    2022不是预警期刊了么

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后,在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1229421, encodeId=7ee112294215e, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:4月28投稿,6月22接受。十分顺利,没有任何不顺心的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Wed Jun 29 11:41:17 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100443, encodeId=7efa210044327, content=感谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fdf6504446, createdName=ms3000000235546431, createdTime=Mon Nov 14 16:37:23 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887762, encodeId=163088e762b0, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:颗粒物;毒理<br>经验分享:已经接收五个多月了,目前还是In production,也没通知缴费,发邮件也没回复,有同行遇到类似问题吗?什么情况?大约多久缴费以及多久可以在线发表呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfd45421024, createdName=ms8000000548825590, createdTime=Wed Sep 23 21:16:54 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094599, encodeId=7666209459987, content=偏重的研究方向:药理;中药复方<br>经验分享:请问收网络药理加实验吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65c58189363, createdName=ms5000001622730751, createdTime=Tue Oct 18 22:49:30 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883395, encodeId=fa1788339512, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:Reprints交费页面,大家怎么处理的?不想再花钱订Reprints了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200907/5e2ae8ab60144029a95cc6c18a379ac1/022cee82a6fa4b7487cb2c3e007d4e48.jpg, createdBy=9fbf96637, createdName=ms5000000364586422, createdTime=Mon Sep 07 20:27:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218747, encodeId=f3b71218e475b, content=去年12月末投稿同出版社的其他期刊,今年2月末给修回并让转投ETM这本,4月初交回去之后没几天通知accepted。接受之后总共对proof修改了三四回,4月末交了版面费,5月官网显示published,但PubMed上还没能搜到。<br>请问一下大家大概在published到PubMed能搜到大概需要多长时间呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d536153686, createdName=ms6000001101669014, createdTime=Wed May 11 15:04:04 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241863, encodeId=fa46124186383, content=审稿一般要多久啊,2个月了一点消息没有,这个杂志under review是送外审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172f6389910, createdName=ms5000001731462752, createdTime=Mon Aug 29 16:47:19 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238113, encodeId=74b7123811306, content=2022不是预警期刊了么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81df5402031, createdName=乐心肠, createdTime=Thu Aug 11 19:17:19 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233784, encodeId=7f9a1233e845f, content=请问投过的战友 这个杂志要求查重率低于多少?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0cf5709748, createdName=ms7000001267392139, createdTime=Thu Jul 21 09:26:53 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2022-07-21 ms7000001267392139

    请问投过的战友 这个杂志要求查重率低于多少?

    0

共500条页码: 3/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分